<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02389218</url>
  </required_header>
  <id_info>
    <org_study_id>2013/1113</org_study_id>
    <nct_id>NCT02389218</nct_id>
  </id_info>
  <brief_title>A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF</brief_title>
  <acronym>METACSA</acronym>
  <official_title>A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent Atrial Fibrilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective trial comparing the efficacy and safety of CryoBalloonAblation (CBA) to
      standardized medication for treatment of early onset persistent atrial fibrillation (AF)
      without structural heart disease. The value of CBA in these patients has never been studied;
      the endpoints for persistent patients are much easier than for paroxysmal patients. Reduction
      in left atrial (LA) size will be compared versus patients on drug therapy and versus failing
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total AF history should be shorter than 24 months. Symptomatic patients can be included
      if they have had within the last year at least 2 episodes of documented AF, lasting minimal
      30 sec. One episode in the entire history should have lasted more than 48 h, requiring
      electrical or pharmacological cardioversion or stopped spontaneously after more than 7 days.

      All patients eligible for the study will sign informed consent, have an echocardiogram prior
      to inclusion to exclude severe left ventricular dysfunction, to rule out significant valve
      abnormalities, left ventricular hypertrophy and to assess the LA volume and diameter.

      Prior to randomization, and after inclusion it is suggested to the local investigators to
      perform an MRI-scan or CT scan of the LA and pulmonary veins (in both branches of the study )
      in eligible patients to assess the anatomy and the left atrial volume. The results should not
      influence the strategy of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sinus rhythm</measure>
    <time_frame>one year</time_frame>
    <description>Sinus rhythm at one year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction LA volume</measure>
    <time_frame>one year</time_frame>
    <description>Reduction left atrial volume in successfully treated patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cardioversions</measure>
    <time_frame>one year</time_frame>
    <description>Number of cardioversions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage on anti arrhythmic drugs (AAD)</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage on AAD in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage on AAD</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage on AAD in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular complications</measure>
    <time_frame>one year</time_frame>
    <description>Vascular complications, including tamponade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke, transient ischemic attack (TIA)</measure>
    <time_frame>one year</time_frame>
    <description>Stroke, TIA (symptomatic)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events (SAE)</measure>
    <time_frame>one year</time_frame>
    <description>Adverse events leading to admission or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom of AF</measure>
    <time_frame>one year</time_frame>
    <description>Freedom of atrial fibrillation with all means</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">167</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Cryoablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cryoballoon single ablation (as described in the reference) at entry after randomization to this group. Single procedure,not to be repeated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional, available anti arrhythmic drugs (propafenone, sotalol or flecainide), in a first stage, sequential, with amiodarone in second stage</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>single ablation (CryoBalloonAblation (CBA)</intervention_name>
    <description>Cryoablation at entry, after randomization to this group</description>
    <arm_group_label>Cryoablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sequential drug adjustment (propafenone, sotalol or flecainide)</intervention_name>
    <description>Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 21 years and legally capable

          -  First documentation or history of symptomatic AF more than 30 sec within the last 2
             years

          -  Twice AF within the last year

          -  One episode cardioverted after more than 48 hours or spontaneously terminated after
             more than 7 days

          -  Eligible for at least one first step drug therapy (sotalol, propafenone, or
             flecainide) and for amiodarone

          -  Left ventricular ejection fraction estimated &gt; 45%

          -  LA diameter &lt; 50 mm (parasternal short axis) and LA volume less than 100 ml (apical
             view, Area Length method;)

          -  CHADS2 â‰¤ 2

          -  Failed AAD strategy, or untreated with AAD

          -  No use of Amiodarone in the previous 3 months (except IV or oral for 7 days)

          -  Informed consent

        Exclusion Criteria:

          -  Age &gt; 75 yrs

          -  CHF

          -  Ischemic heart disease as known in the history

          -  (Severe) Left ventricular hypertrophy as shown on echo (IVSd or PWd &gt; 14 mm)

          -  Hyperthyroidism

          -  Congenital heart disease

          -  Hypertrophic Cardiomyopathy, Arrhythmogenic Right ventricular Cardiomyopathy,
             channelopathies

          -  Contra-indications to AAD

          -  Long QT syndrome

          -  Received already adequately dosed all level 1 drugs (sotalol, propafenone, and
             flecainide)

          -  Pure (typical) atrial flutter as documented on one occasion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc Jordaens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pieter Vervaet</last_name>
    <phone>+3293324349</phone>
    <email>pieter.vervaet@uzgent.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michel De Pauw, MD</last_name>
    <phone>+3293323460</phone>
    <email>Michel.DePauw@uzgent.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brussels Heart Centre</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc Jordaens, MD</last_name>
      <phone>+3228910961</phone>
      <email>ljordaens@clstjean.be</email>
    </contact>
    <contact_backup>
      <last_name>Peter Goethals, MD</last_name>
      <phone>+3228910961</phone>
      <email>pgoethals@clstjean.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Saint Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Benoit Le Polain De Waroux, MD, PhD</last_name>
      <phone>+3227642888</phone>
      <email>jblpdw@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept Cardiologie</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Van Heuverswyn, MD</last_name>
      <phone>+3293323459</phone>
      <email>Frederic.VanHeuverswyn@uzgent.be</email>
    </contact>
    <contact_backup>
      <last_name>Luc Jordaens, MD, Phd</last_name>
      <phone>+3293323459</phone>
      <email>l.jordaens@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Van Belle Y, Janse P, Theuns D, Szili-Torok T, Jordaens L. One year follow-up after cryoballoon isolation of the pulmonary veins in patients with paroxysmal atrial fibrillation. Europace. 2008 Nov;10(11):1271-6. doi: 10.1093/europace/eun218.</citation>
    <PMID>18955409</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2015</study_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>cryoablation</keyword>
  <keyword>catheter ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flecainide</mesh_term>
    <mesh_term>Sotalol</mesh_term>
    <mesh_term>Propafenone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

